Vivien A. Sheehan

Nov 17, 2024 | onlinelibrary.wiley.com | Alka A. Potdar |G. Yu |Greg Gibson |Vivien A. Sheehan

CONFLICT OF INTEREST STATEMENT Vivien A. Sheehan receives research funding from Beam Therapeutics, Pfizer, Novartis, and Agios. Alka A. Potdar and G. Karen Yu are former employees of Pfizer. Supporting Information Filename Description bjh19839-sup-0001-FigS1-S2.docxWord 2007 document , 355 KB Figure S1. Figure S2. bjh19839-sup-0002-TableS1.xlsxExcel 2007 spreadsheet , 248.3 KB Table S1. bjh19839-sup-0003-TableS3.xlsxExcel 2007 spreadsheet , 14.1 KB Table S2.

Mar 26, 2024 | cgtlive.com | Vivien A. Sheehan

“The big take home message to me is that we need to have the decision to go forward with a cell-based therapy be the patient and their family's choice and not be paternalistic and say ‘You must try every FDA-approved therapy for SCD first.’ Not only is that inappropriate, but their level of benefit, even with good response does not equal that of a cell-based therapy, nor does transfusion.” Historically, the small molecule drug hydroxyurea has been the main treatment option for patients with...